scholarly journals Conference 2015: Drug Discovery and Development in the Post Genomic Era. An international symposium held jointly by CSPS and CC-CRS, May 26-28, 2015, Toronto, ON, Canada

2015 ◽  
Vol 18 (3) ◽  
pp. 1
Author(s):  
Beverley Berekoff
Keyword(s):  
Drug Discovery ◽  
Drug Targets ◽  
New Technologies ◽  
Pharmaceutical Sciences ◽  
Drug Discovery And Development ◽  
University Of Toronto ◽  
Genome Wide ◽  
Lifetime Achievement ◽  
New Methodologies ◽  
University Of Manitoba

Plenaries and Special Presentations:Shana Kelley, University of Toronto:  "New Technologies for Ultrasensitive Analysis of Clinically-relevant Biomolecules"Richard Hargreaves, BIOGEN IDEC:  "Imaging in CNS Drug Discovery and Development"Roger Williams:  CSPS Lifetime Achievement Award - "0.5 X 102:  Looking Back and Forward"Neal Davies, University of Manitoba:  CSPS Award of Leadership in Canadian Pharmaceutical Sciences - "30 Years of Coffee, Beer and Serendipity in Pharmacy Research"Conference Sessions:Special CSPS Session: The Future of Pharmaceutical Sciences1. The Evolving Business of Pharmaceuticals2. Analysis of Peptide and Protein Drug Targets by LC/MS/MS3. Mucosal Drug Delivery4. New Methodologies of Genome Wide Target Validation5. Regulatory Updates and Developments6. Antibody-based Therapeutics7. Imaging in Drug Delivery8. Nuclear Receptors in Drug Discovery9. IV-IVC Modeling and Simulation as a Tool to Facilitate Drug Development and Marketing10. Pharmacogenomics in Drug Development11. Bioavailability of Novel Dosage Forms

scholarly journals Conference 2016: From Drug Discovery to Health Outcomes: Population to Patient. An international symposium held jointly by CSPS and CC-CRS, May 31-June 3, 2016, Vancouver, BC, Canada

2016 ◽  
Vol 19 (3) ◽  
pp. 1
Author(s):  
Beverley Berekoff
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Research ◽  
Lessons Learned ◽  
Knowledge Generation ◽  
Pharmaceutical Sciences ◽  
University Of Alberta ◽  
University Of Toronto ◽  
Lifetime Achievement ◽  
Life Sciences Industry ◽  
Pharmaceutical Research And Development

Plenaries and Special Presentations:Carolyn Buser-Doepner, GSK:  "New Trends in Pharma-Academia Collaborations for Drug Discovery"Chris Halyk, President, Janssen Inc.:  "Are Innovative Medicines and our Life Sciences Industry at Risk in Canada?"Aaron Schimmer, Princess Margaret Cancer Centre:  "New Therapeutic Strategies to Target the Mitochondria in Leukemia"Ivana Cecic, Genome BC:  "Genomics in Canada: From Knowledge Generation to Patient Outcomes"Adam Rosebrock, University of Toronto:  "Quantitative Mass-Spectrometry Metabolomics for Direct Biochemical Phenotyping"Fakhreddin Jamali, University of Alberta: CSPS Lifetime Achievement Award Lecture - "Pharmaceutical Research and Development, Lessons Learned"Conference Sessions:Special Session: Innovation and Management of Modern Pharmaceuticals1. Special Populations2. Nanomedicines Become Personal: Opportunities and Challenges3. Mucosal Drug Delivery4. Broaching the Fourth Hurdle: Getting Drugs on the Formulary5. Pharmacogenomics in the Clinic and Community6. Responsive Drug Delivery Systems7. Drug Targeting and Targeting Drugs8. Health Sustainability Evidence9. Integrating Pharmaceutical Sciences into a Pharm D Curriculum10. Analytical Innovation to Support Precision Medicine and Biologicals Development11. Protein and Peptide Delivery

scholarly journals Genomics-driven drug discovery based on disease-susceptibility genes

2021 ◽  
Vol 41 (1) ◽  
Author(s):  
Kyuto Sonehara ◽  
Yukinori Okada
Keyword(s):  
Drug Discovery ◽  
Drug Targets ◽  
Disease Susceptibility ◽  
Mendelian Randomization ◽  
Association Studies ◽  
Drug Repurposing ◽  
Susceptibility Genes ◽  
Genome Wide Association Studies ◽  
Genome Wide ◽  
Disease Associations

AbstractGenome-wide association studies have identified numerous disease-susceptibility genes. As knowledge of gene–disease associations accumulates, it is becoming increasingly important to translate this knowledge into clinical practice. This challenge involves finding effective drug targets and estimating their potential side effects, which often results in failure of promising clinical trials. Here, we review recent advances and future perspectives in genetics-led drug discovery, with a focus on drug repurposing, Mendelian randomization, and the use of multifaceted omics data.

The impact of molecular biology on drug discovery

2006 ◽  
Vol 34 (2) ◽  
pp. 313-316 ◽  
Author(s):  
G.P. Belfield ◽  
S.J. Delaney
Keyword(s):  
Drug Discovery ◽  
Molecular Biology ◽  
Clinical Efficacy ◽  
Drug Targets ◽  
Safety Data ◽  
Vital Role ◽  
Drug Discovery And Development ◽  
New Drug ◽  
Whole Process ◽  
The Impact

The discipline of molecular biology has become increasingly important in recent times for the process of drug discovery. We describe the impact of molecular biology across the whole process of drug discovery and development, including (i) the identification and validation of new drug targets, (ii) the development of molecular screens to find new candidate drugs, and (iii) the generation of safety data and competences leading to enhanced clinical efficacy. We also speculate on emerging developments in drug discovery where it seems likely that molecular biology will play an even more vital role in the generation of future therapies.

scholarly journals Academic Discovery of Anticancer Drugs: Historic and Future Perspectives

2019 ◽  
Vol 3 (1) ◽  
pp. 385-408 ◽  
Author(s):  
Alessandro Carugo ◽  
Giulio F. Draetta
Keyword(s):  
Drug Discovery ◽  
Anticancer Drug ◽  
Cancer Biology ◽  
Drug Targets ◽  
Nonprofit Sector ◽  
Critical Issue ◽  
Drug Discovery And Development ◽  
New Horizons ◽  
Innovation Research ◽  
History Of

The identification and prosecution of meritorious anticancer drug targets and the discovery of clinical candidates represent an extraordinarily time- and resource-intensive process, and the current failure rate of late-stage drugs is a critical issue that must be addressed. Relationships between academia and industry in drug discovery and development have continued to change over time as a result of technical and financial challenges and, most importantly, to the objective of translating impactful scientific discoveries into clinical opportunities. This Golden Age of anticancer drug discovery features an increased appreciation for the high-risk, high-innovation research conducted in the nonprofit sector, with the goals of infusing commercial drug development with intellectual capital and curating portfolios that are financially tenable and clinically meaningful. In this review, we discuss the history of academic-industry interactions in the context of antidrug discovery and offer a view of where these interactions are likely headed as we continue to reach new horizons in our understanding of the immense complexities of cancer biology.

Schizophrenia drug discovery and development in an evolving era: Are new drug targets fulfilling expectations?

2015 ◽  
Vol 29 (2) ◽  
pp. 230-238 ◽  
Author(s):  
John Dunlop ◽  
Nicholas J Brandon
Keyword(s):  
Drug Discovery ◽  
Drug Targets ◽  
Negative Symptoms ◽  
Metabotropic Glutamate Receptor ◽  
Dopamine D2 Receptor ◽  
D2 Receptor ◽  
Therapeutic Benefit ◽  
Receptor Subtype ◽  
Drug Discovery And Development ◽  
Alpha7 Nicotinic Acetylcholine Receptor

Current therapeutics for schizophrenia, the typical and atypical antipsychotic class of drugs, derive their therapeutic benefit predominantly by antagonism of the dopamine D2 receptor subtype and have robust clinical benefit on positive symptoms of the disease with limited to no impact on negative symptoms and cognitive impairment. Driven by these therapeutic limitations of current treatments and the recognition that transmitter systems beyond the dopaminergic system in particular glutamatergic transmission contribute to the etiology of schizophrenia significant recent efforts have focused on the discovery and development of novel treatments for schizophrenia with mechanisms of action that are distinct from current drugs. Specifically, compounds selectively targeting the metabotropic glutamate receptor 2/3 subtype, phosphodiesterase subtype 10, glycine transporter subtype 1 and the alpha7 nicotinic acetylcholine receptor have been the subject of intense drug discovery and development efforts. Here we review recent clinical experience with the most advanced drug candidates targeting each of these novel mechanisms and discuss whether these new agents are living up to expectations.

An overview of drug discovery and development

2020 ◽  
Vol 12 (10) ◽  
pp. 939-947 ◽  
Author(s):  
Nurken Berdigaliyev ◽  
Mohamad Aljofan
Keyword(s):  
Drug Discovery ◽  
High Throughput ◽  
Combinatorial Chemistry ◽  
New Technologies ◽  
Drug Repurposing ◽  
Drug Discovery And Development ◽  
Advantages And Disadvantages ◽  
High Throughput Drug Screening ◽  
The Cost ◽  
Early Drug

A new medicine will take an average of 10–15 years and more than US$2 billion before it can reach the pharmacy shelf. Traditionally, drug discovery relied on natural products as the main source of new drug entities, but was later shifted toward high-throughput synthesis and combinatorial chemistry-based development. New technologies such as ultra-high-throughput drug screening and artificial intelligence are being heavily employed to reduce the cost and the time of early drug discovery, but they remain relatively unchanged. However, are there other potentially faster and cheaper means of drug discovery? Is drug repurposing a viable alternative? In this review, we discuss the different means of drug discovery including their advantages and disadvantages.

scholarly journals Translational precision medicine: an industry perspective

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Dominik Hartl ◽  
Valeria de Luca ◽  
Anna Kostikova ◽  
Jason Laramie ◽  
Scott Kennedy ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Drug Discovery ◽  
Precision Medicine ◽  
Paradigm Shift ◽  
Development Process ◽  
New Technologies ◽  
Traditional Approach ◽  
Drug Discovery And Development ◽  
Development Face ◽  
Digital Biomarkers

AbstractIn the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally changing the traditional approach of how drugs are discovered, developed and marketed. Critical to this transformation is the adoption of new technologies in the drug development process, catalyzing the transition from serendipity-driven to data-driven medicine. This paradigm shift comes with a need for both translation and precision, leading to a modern Translational Precision Medicine approach to drug discovery and development. Key components of Translational Precision Medicine are multi-omics profiling, digital biomarkers, model-based data integration, artificial intelligence, biomarker-guided trial designs and patient-centric companion diagnostics. In this review, we summarize and critically discuss the potential and challenges of Translational Precision Medicine from a cross-industry perspective.

scholarly journals Role of pharmaceutical sciences in future drug discovery

2021 ◽  
Vol 3 (3) ◽  
Author(s):  
Srinivasa Reddy Bonam ◽  
Mahendran Sekar ◽  
Girija S Guntuku ◽  
Sridhar G Nerella ◽  
Krishna M Pawar A ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Translational Research ◽  
Pharmacy Education ◽  
Pharmaceutical Sciences ◽  
Next Generation ◽  
Drug Discovery And Development ◽  
Recent Emergence ◽  
Future Drug

The recent emergence of COVID-19 influenced the layman’s knowledge of drugs. Although several drugs have been discovered serendipitously, research has moved to the next-generation era of drug discovery. The use of drugs is inevitable and they have become lifesavers in the present era. Although research from different scientific backgrounds has supported the translational research of drug discovery, the prime role of pharmacy has to be remembered. Here we have summarized the role of some important subjects in pharmacy education, which have paved different ways in drug discovery and development.

Sign in / Sign up

Export Citation Format

Share Document